Rapport Therapeutics 3Q 2026: Revenue $0 Net loss $40.2M, EPS $(0.84) — 10-Q Summary
Rapport Therapeutics reported no revenue and a net loss of $40.2M in 3Q 2026, widening from a $26.9M loss in the prior-year quarter. Diluted EPS was $(0.84). The company began Phase 3 trials for RAP-219 in epilepsy and plans further trials in 2027. Collaboration revenue from Tenacia was $20M for the nine months. According to the company, they deferred one program and prioritized another.
How this was made
The 30-second read
Why it matters
The earnings miss may trigger short‑term sell‑off, but upcoming trial data could provide a catalyst later in 2027.
Market read
Primary earnings disclosure for a micro‑cap biotech; likely short‑term downside with potential upside from future trial milestones.
What to watch
The $20 M collaboration revenue from Tenacia and potential future trial data could offset short‑term earnings weakness.
Background
Rapport Therapeutics is a clinical‑stage biotech focused on neurological and pain indications. The 10‑Q details trial progress and collaboration revenue.
Ticker impact
Rapport Therapeutics filed its 3Q 2026 10‑Q showing $0 revenue and a widened net loss of $40.2 M versus $26.9 M a year ago.
likely pressure as the market prices in the widened loss and lack of revenue
Earnings release is the first public disclosure of these numbers; investors typically react negatively to a loss widening and no revenue.
Market effects
Highlights continued cash burn in the biotech sector, may pressure peer small‑cap biotech stocks.
Limited to U.S. biotech investors; no broader regional effect.
Minimal; the news is company‑specific.
Counterpoint
If the upcoming Phase 3 trials for RAP‑219 succeed, the stock could rebound despite the current loss.
Key entities
- companyRapport Therapeutics
Clinical‑stage biotech reporting Q3 2026 results.
- partnerTenacia
Collaboration partner providing $20 M upfront payment.
